Metagenomi, Inc. [•] Shares of Common Stock Underwriting AgreementUnderwriting Agreement • February 5th, 2024 • Metagenomi, Inc. • Biological products, (no disgnostic substances) • New York
Metagenomi, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [•] shares of common stock, par value $0.0001 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [•] shares of common stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”.
METAGENOMI, INC. FORM OF INDEMNIFICATION AGREEMENTIndemnification Agreement • February 5th, 2024 • Metagenomi, Inc. • Biological products, (no disgnostic substances) • Delaware
This Indemnification Agreement (“Agreement”) is made as of [Date] by and between Metagenomi, Inc., a Delaware corporation (the “Company”), and [Director Name] (“Indemnitee”).
METAGENOMI, INC. REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • February 5th, 2024 • Metagenomi, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS REGISTRATION RIGHTS AGREEMENT (the “Agreement”) is entered into as of January 24, 2024, by and among Metagenomi, Inc., a Delaware corporation (the “Company”), and the investors listed on Exhibit A hereto, referred to hereinafter as the “Investors” and each individually as an “Investor.”
AGREEMENT AND PLAN OF MERGERMerger Agreement • February 5th, 2024 • Metagenomi, Inc. • Biological products, (no disgnostic substances) • Delaware
This Agreement and Plan of Merger (this “Agreement”) is entered into as of January 24, 2024, by and among Metagenomi Technologies, LLC a Delaware limited liability company (the “Parent”) and Metagenomi, Inc., a Delaware corporation and wholly owned subsidiary of Parent (the “Company”).
